Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Fludarabine (F), Rituxan (R) and Avastin (A) Followed by RA Maintenance in Patients With Relapsed/Refractory B-cell Chronic Lymphocytic Leukemia (CLL)

NCT00845104 is registered in ClinicalTrials.gov with Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium as lead sponsor.

NCT NCT00845104
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00845104 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Fludarabine (F), Rituxan (R) and Avastin (A) Followed by RA Maintenance in Patients With Relapsed/Refractory B-cell Chronic Lymphocytic Leukemia (CLL)
Lead sponsor
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Phase
Phase 2
Overall status
Withdrawn
Start date
January 31, 2009
Completion date
Not reported
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell chronic lymphocytic leukemia, refractory chronic lymphocytic leukemia